NeoGenomics shares are trading higher after the company announced that its RaDaR ST molecular residual disease assay has received expanded coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.

NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors

New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions

Greenland Mines Outlines $2B Valuation for Sarfartoq Project

Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.

NeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.